MoonLake Immunotherapeutics
MLTX
$39.65
$0.982.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.04% | 36.81% | 54.31% | 23.38% | 30.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 229.90% | 232.23% | 131.90% | 53.27% | -9.99% |
| Operating Income | -229.90% | -232.23% | -131.90% | -53.27% | 9.99% |
| Income Before Tax | -491.02% | -210.79% | -99.95% | -13.90% | 52.34% |
| Income Tax Expenses | -7.22% | 218.69% | 679.21% | 539.09% | 302.73% |
| Earnings from Continuing Operations | -488.23% | -210.81% | -100.42% | -14.38% | 52.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 75.71% | -66.99% | -77.79% | -90.61% | 170.37% |
| Net Income | -513.20% | -275.45% | -139.34% | -51.85% | 56.53% |
| EBIT | -229.90% | -232.23% | -131.90% | -53.27% | 9.99% |
| EBITDA | -229.14% | -232.06% | -131.75% | -53.13% | 12.13% |
| EPS Basic | -482.68% | -219.53% | -66.45% | 5.29% | 71.82% |
| Normalized Basic EPS | -501.35% | -266.95% | -88.79% | -18.50% | 73.59% |
| EPS Diluted | -482.68% | -219.53% | -66.45% | 5.29% | 71.82% |
| Normalized Diluted EPS | -501.35% | -266.95% | -88.79% | -18.50% | 73.59% |
| Average Basic Shares Outstanding | 5.27% | 17.53% | 43.82% | 60.35% | 54.24% |
| Average Diluted Shares Outstanding | 5.27% | 17.53% | 43.82% | 60.35% | 54.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
